224 related articles for article (PubMed ID: 23109704)
21. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
22. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
23. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.
Sigurdson AJ; Hauptmann M; Chatterjee N; Alexander BH; Doody MM; Rutter JL; Struewing JP
BMC Cancer; 2004 Mar; 4():9. PubMed ID: 15113441
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
25. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
26. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
[TBL] [Abstract][Full Text] [Related]
27. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
28. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
[TBL] [Abstract][Full Text] [Related]
30. Can unknown predisposition in familial breast cancer be family-specific?
Lynch H; Wen H; Kim YC; Snyder C; Kinarsky Y; Chen PX; Xiao F; Goldgar D; Cowan KH; Wang SM
Breast J; 2013; 19(5):520-8. PubMed ID: 23800003
[TBL] [Abstract][Full Text] [Related]
31. Common low-penetrance risk variants associated with breast cancer in Polish women.
Ledwoń JK; Hennig EE; Maryan N; Goryca K; Nowakowska D; Niwińska A; Ostrowski J
BMC Cancer; 2013 Oct; 13():510. PubMed ID: 24171766
[TBL] [Abstract][Full Text] [Related]
32. Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.
Robson ME; Reiner AS; Brooks JD; Concannon PJ; John EM; Mellemkjaer L; Bernstein L; Malone KE; Knight JA; Lynch CF; Woods M; Liang X; Haile RW; Duggan DJ; Shore RE; Smith SA; Thomas DC; Stram DO; Bernstein JL;
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521362
[TBL] [Abstract][Full Text] [Related]
33. RASSF1A polymorphism in familial breast cancer.
Bergqvist J; Latif A; Roberts SA; Hadfield KD; Lalloo F; Howell A; Evans DG; Newman WG
Fam Cancer; 2010 Sep; 9(3):263-5. PubMed ID: 20361264
[TBL] [Abstract][Full Text] [Related]
34. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
Jiao Y; Truong T; Eon-Marchais S; Mebirouk N; Caputo SM; Dondon MG; Karimi M; Le Gal D; Beauvallet J; Le Floch É; Dandine-Roulland C; Bacq-Daian D; Olaso R; Albuisson J; Audebert-Bellanger S; Berthet P; Bonadona V; Buecher B; Caron O; Cavaillé M; Chiesa J; Colas C; Collonge-Rame MA; Coupier I; Delnatte C; De Pauw A; Dreyfus H; Fert-Ferrer S; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Golmard L; Lasset C; Lejeune-Dumoulin S; Léoné M; Limacher JM; Lortholary A; Luporsi É; Mari V; Maugard CM; Mortemousque I; Mouret-Fourme E; Nambot S; Noguès C; Popovici C; Prieur F; Pujol P; Sevenet N; Sobol H; Toulas C; Uhrhammer N; Vaur D; Venat L; Boland-Augé A; Guénel P; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Eur J Cancer; 2023 Jan; 179():76-86. PubMed ID: 36509001
[TBL] [Abstract][Full Text] [Related]
35. Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.
Walker LC; Pearson JF; Wiggins GA; Giles GG; Hopper JL; Southey MC
Breast Cancer Res; 2017 Mar; 19(1):30. PubMed ID: 28302160
[TBL] [Abstract][Full Text] [Related]
36. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis.
Tun NM; Villani G; Ong K; Yoe L; Bo ZM
Clin Genet; 2014 Jan; 85(1):43-8. PubMed ID: 24000781
[TBL] [Abstract][Full Text] [Related]
37. Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
Lonjou C; Eon-Marchais S; Truong T; Dondon MG; Karimi M; Jiao Y; Damiola F; Barjhoux L; Le Gal D; Beauvallet J; Mebirouk N; Cavaciuti E; Chiesa J; Floquet A; Audebert-Bellanger S; Giraud S; Frebourg T; Limacher JM; Gladieff L; Mortemousque I; Dreyfus H; Lejeune-Dumoulin S; Lasset C; Venat-Bouvet L; Bignon YJ; Pujol P; Maugard CM; Luporsi E; Bonadona V; Noguès C; Berthet P; Delnatte C; Gesta P; Lortholary A; Faivre L; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Mazoyer S; Monraz LC; Kondratova M; Kuperstein I; Guénel P; Barillot E; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Int J Cancer; 2021 Apr; 148(8):1895-1909. PubMed ID: 33368296
[TBL] [Abstract][Full Text] [Related]
38. The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance.
Skol AD; Sasaki MM; Onel K
Breast Cancer Res; 2016 Oct; 18(1):99. PubMed ID: 27716388
[TBL] [Abstract][Full Text] [Related]
39. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer.
Wirtenberger M; Tchatchou S; Hemminki K; Schmutzhard J; Sutter C; Schmutzler RK; Meindl A; Wappenschmidt B; Kiechle M; Arnold N; Weber BH; Niederacher D; Bartram CR; Burwinkel B
Carcinogenesis; 2006 Nov; 27(11):2201-8. PubMed ID: 16704985
[TBL] [Abstract][Full Text] [Related]
40. Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.
Yanes T; Meiser B; Young MA; Kaur R; Mitchell G; Barlow-Stewart K; Roscioli T; Halliday J; James P
BMC Cancer; 2017 Jul; 17(1):491. PubMed ID: 28720130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
